-
公开(公告)号：KR1020160073950A
公开(公告)日：2016-06-27
申请号：KR1020160071842
申请日：2016-06-09
Applicant: (주)아모레퍼시픽
CPC classification number: A61K36/48 , A23L33/105 , A23V2200/30 , A23V2200/326
Abstract: 본발명은유색콩등으로부터추출한유색콩추출물및 그분획물을유효성분으로함유하는항혈전효능조성물에관한것이다. 본발명에의한항혈전조성물은아데노신을포함하고있으며, 혈전형성의원인이되는심장혈관질환, 뇌혈관질환, 동맥경화증, 고혈압, 당뇨등의순환기계질환의치료에매우유용하게이용될수 있다.
Abstract translation: 本发明涉及抗紫外线组合物，其含有作为活性成分的从有色豆及其部分提取的有色豆提取物。 本发明的抗血栓形成组合物含有腺苷，可用于治疗血栓形成原因的心血管疾病，脑血管疾病，动脉粥样硬化，高血压，糖尿病等循环系统疾病。
-
公开(公告)号：KR101210008B1
公开(公告)日：2012-12-07
申请号：KR1020050104962
申请日：2005-11-03
Applicant: (주)아모레퍼시픽
IPC: A61K31/685 , A61K31/66
Abstract: 본발명은스핑고실포스포릴콜린(Sphingosylphosphorylcholine; SPC) 또는그 유도체의용도에관한것으로서, 보다상세하게는상기스핑고실포스포릴콜린의투여량을조절하여동물에가려움을유발하는방법, 가려움증억제물질을스크리닝하는방법및 스크리닝한가려움증억제물질의약효를평가하는방법에관한것이다. 본발명에의한스핑고실포스포릴콜린또는그 유도체는가려움증을이해하고연구하는데유용하며, 이를바탕으로가려움증치료약을검색하거나약효를평가하여개발하는데매우유용하게사용될수 있다.
-
Patent Agency Ranking
公开(公告)号：KR1020120027432A
公开(公告)日：2012-03-21
申请号：KR1020117031657
申请日：2010-06-18
Applicant: (주)아모레퍼시픽
CPC classification number: A23L33/105 , A23V2002/00 , A23V2200/318
Abstract: PURPOSE: Health food or pharmaceutical composition including containing a chestnut skin extract is provided to reduce the pruritus of a user. CONSTITUTION: Health food or pharmaceutical composition contains 0.005-80wt% of chestnut skin extract for reducing or controlling the pruritus of a user. The chestnut skin is selected from the inner skin, the outer skin, or their mixture. The chestnut skin extract is obtained by extracting the chestnut skin using water, low class alcohol having 1-4 carbons, 1,3-butyl glycol, or their mixed solution.
Abstract translation: 目的：提供包含栗子皮肤提取物的保健食品或药物组合物，以减少使用者的瘙痒。 规定：保健食品或药物组合物含有0.005-80wt％的栗子皮肤提取物，用于减少或控制使用者的瘙痒。 板栗皮肤选自内皮，外皮或其混合物。 栗子皮提取物是通过使用水，含1-4碳的低级醇，1,3-丁二醇或它们的混合溶液提取栗子皮来获得的。
-
34.发明授权
公开(公告)号：KR101018819B1
公开(公告)日：2011-03-04
申请号：KR1020087019182
申请日：2007-02-14
Applicant: (주)아모레퍼시픽
IPC: A61K31/17 , A61K31/765 , A61P17/00
CPC classification number: A61K9/0014 , A61K31/17 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/32
Abstract: 본 발명은 바닐로이드 수용체 길항제로서 티오우레아 유도체와 약제학적으로 허용가능한 담체를 함유하는 외용제 조성물 및 이의 약제학적 용도에 관한 것이다.
본 발명의 외용제 조성물은 피부투과와 안정성에서 우수하며 소양성 또는 자극성 피부질환에 유용하다.-
公开(公告)号：KR1020080051235A
公开(公告)日：2008-06-11
申请号：KR1020060121955
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/12 , A61K31/05 , A61K31/136 , A61P3/04
Abstract: A pharmaceutical composition for treating and preventing lipid metabolism-related diseases is provided to increase activity of isocitrate dehydrogenase 3alpha(IDH3alpha) promoter and carnitine palmitoyl transferase 1A(CPT1A) promoter, so that blood sugar and neutral fat are reduced. A pharmaceutical composition for treating and preventing lipid metabolism-related diseases comprises compounds represented by the formula(1), wherein R1 is H or C1-C5 alkyl, R2 is H or OH and n is an integer from 1 to 3, and is formulated as tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, sterile injection solution or sterile powder, wherein the daily dosage of the compounds is 0.1-100 mg/kg. Further, the lipid metabolism-related diseases are obesity, hyperlipemia and diabetes.
Abstract translation: 提供了用于治疗和预防脂质代谢相关疾病的药物组合物，以增加异柠檬酸脱氢酶3α（IDH3alpha）启动子和肉碱棕榈酰转移酶1A（CPT1A）启动子的活性，从而降低血糖和中性脂肪。 用于治疗和预防脂质代谢相关疾病的药物组合物包括由式（1）表示的化合物，其中R 1为H或C 1 -C 5烷基，R 2为H或OH，n为1至3的整数， 作为片剂，丸剂，粉末，香囊，酏剂，悬浮液，乳剂，溶液，糖浆，气溶胶，软或硬明胶胶囊，无菌注射溶液或无菌粉末，其中化合物的日剂量为0.1-100mg / kg。 此外，脂质代谢相关疾病是肥胖，高脂血症和糖尿病。
-
36.发明授权3,4-메틸렌디옥시벤젠 또는 3,4-에틸렌디옥시벤젠 모핵을가지는 4-치환된 벤조산 유도체 화합물을 함유하는항노화용 화장료 조성물 有权含有3,4-取代的苯甲酸衍生物的抗化妆品组合物，其具有3,4-亚甲基或3,4-乙烯基二苯甲酮
公开(公告)号：KR100786300B1
公开(公告)日：2007-12-18
申请号：KR1020060090560
申请日：2006-09-19
Applicant: (주)아모레퍼시픽
Abstract: A 4-substituted benzoic acid derivative compound having 3,4-methylenedioxybenzene or 3,4-ethylenedioxybenzene moiety is provided to promote the biosynthesis of main constituents of skin dermis such as collagen, elastin, fibrillin, glycosaminoglycan(GAG) closely related to skin wrinkles, thereby being usefully used as medicines and skin external applying agents for preventing aging and improving the wrinkles. An anti-aging cosmetic composition comprises 0.01-20.0 wt.% of a 4-substituted benzoic acid derivative compound having 3,4-methylenedioxybenzene or 3,4-ethylenedioxybenzene moiety and represented by the formula(I), wherein R1 is -CH2- or -CH2=CH2-, R2 is the structural formula(Ia), and R3 is H, methyl or ethyl. A method for preparing the 4-substituted benzoic acid derivative compound comprises the steps of: (a) preparing a compound(1) represented by the formula(1) from 3,4-methylenedioxybenzoic acid or 3,4-ethylenedioxybenzoic acid; and (b) hydrolyzing the compound of the formula(1) with a base to prepare a compound(2) represented by the formula(2).
Abstract translation: 提供具有3,4-亚甲二氧基苯或3,4-亚乙二氧基苯部分的4-取代苯甲酸衍生物化合物，以促进皮肤真皮主要成分的生物合成，如与皮肤皱纹密切相关的胶原蛋白，弹性蛋白，纤维蛋白，糖胺聚糖（GAG） 从而有效地用作用于防止老化和改善皱纹的药物和皮肤外用施用剂。 抗衰老化妆品组合物包含0.01-20.0重量％的具有3,4-亚甲二氧基苯或3,4-亚乙二氧基苯部分并由式（I）表示的4-取代苯甲酸衍生物化合物，其中R 1是-CH 2 - 或-CH 2 = CH 2 - ，R 2是结构式（Ia），R 3是H，甲基或乙基。 制备4-取代苯甲酸衍生物化合物的方法包括以下步骤：（a）由3,4-亚甲二氧基苯甲酸或3,4-亚乙二氧基苯甲酸制备由式（1）表示的化合物（1） 和（b）用碱水解式（1）的化合物以制备由式（2）表示的化合物（2）。
-
公开(公告)号：KR1020060040869A
公开(公告)日：2006-05-11
申请号：KR1020040089799
申请日：2004-11-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/202 , A61K31/5575
CPC classification number: A61K31/202
Abstract: 본 발명은 아라키돈산 대사물질 또는 그 유도체의 용도에 관한 것으로서, 보다 상세하게는 아라키돈산 대사물질인 12(s)-HPETE, 15(s)-HPETE 또는 그 유도체의 투여량을 조절하여 동물에서 가려움증을 유발하는 방법, 가려움증 억제 물질의 스크리닝 방법 및 그 스크리닝한 가려움증 억제 물질의 약효를 평가하는 방법에 관한 것이다. 본 발명에 의한 아라키돈산 대사물질 또는 그 유도체는 가려움증을 이해하고 연구하는데 유용하며, 이를 바탕으로 가려움증 치료 약을 검색하거나 약효를 평가하여 개발하는데 매우 유용하게 사용될 수 있다.
아라키돈산 대사물질, 12(s)-HPETE, 15(s)-HPETE, 가려움증 억제 물질, 가려움증
-
-
-
-
-
-
Search Results
37
records
(took 0.031 seconds)
